09:01 AM EDT, 08/04/2025 (MT Newswires) -- MaxCyte ( MXCT ) said Monday that it has signed a strategic platform license agreement with Adicet Bio ( ACET ) .
MaxCyte ( MXCT ) said the agreement grants Adicet Bio ( ACET ) non-exclusive research, clinical, and commercial rights to use MaxCyte's ( MXCT ) Flow Electroporation technology and ExPERT platform in exchange for platform licensing fees and program-related revenue.